Moderna Enlists Catalent to Accelerate U.S. Manufacturing of COVID-19 Vaccine

Moderna has expanded its existing agreement with Catalent to boost COVID-19 vaccine production at Catalent’s fill-and-finish facility in Bloomington, Ind., to supply the U.S. market.

Under an existing pact signed in June 2020, Catalent helped fill an initial U.S. government order of 100 million doses of vaccine by the end of March, with a further order of 100 million doses scheduled for delivery by the end of May and a final shipment of 100 million additional doses planned by the end of July.

Under the expanded deal, Catalent is dedicating a new high-speed filling line at its Bloomington site to vaccine production starting next month and will reportedly be able to supply an additional 80 million vaccine doses annually.